SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Share Price
Equities
002399
CNE100000P02
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.22 CNY | +0.33% |
|
+2.56% | -21.40% |
| Sales 2024 * | 5.63B 777M 62.2B | Sales 2025 * | 6.47B 894M 71.56B | Capitalization | 12.15B 1.68B 134B |
|---|---|---|---|---|---|
| Net income 2024 * | 649M 89.57M 7.17B | Net income 2025 * | 739M 102M 8.17B | EV / Sales 2024 * | 2.03 x |
| Net cash position 2024 * | 67.8M 9.36M 749M | Net Debt 2025 * | 4.03B 556M 44.56B | EV / Sales 2025 * | 2.63 x |
| P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
18.4
x | Employees | 2,080 |
| Yield 2024 * |
0.54% | Yield 2025 * |
0.65% | Free-Float | 17.01% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.33% | ||
| 1 week | +2.56% | ||
| Current month | +10.42% | ||
| 1 month | +8.98% | ||
| 3 months | +1.32% | ||
| 6 months | -24.49% | ||
| Current year | -21.40% |
1 week
8.77
9.33
1 month
8.199.33
Current year
6.8911.94
1 year
6.8912.97
3 years
6.8918.89
5 years
6.8930.69
10 years
6.8930.69
| Managers | Title | Age | Since |
|---|---|---|---|
Yu Shan
FOU | Founder | 64 | 20/04/98 |
Tan Li
FOU | Founder | 60 | 20/04/98 |
Juan Chen
DFI | Director of Finance/CFO | 49 | 20/08/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tan Li
FOU | Founder | 60 | 20/04/98 |
Peng Huang
BRD | Director/Board Member | 75 | 21/05/23 |
Li Li
FOU | Founder | 60 | 20/04/98 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 9.22 | +0.33% | 5,152,012 |
| 25/04/24 | 9.19 | +2.68% | 4,711,676 |
| 24/04/24 | 8.95 | +1.02% | 2,884,960 |
| 23/04/24 | 8.86 | -1.12% | 3,106,423 |
| 22/04/24 | 8.96 | -0.33% | 4,246,516 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based pharmaceutical company focused on the field of heparin sodium preparations and raw materials, macromolecular drugs contract development manufacturing organization (CDMO) and innovative drug development. The Companyâs main products and services include enoxaparin sodium preparations and heparin sodium bulk medicines, enoxaparin sodium bulk medicines, and CDMO services for macromolecular drugs. The Company distributes its products within the domestic market and to overseas markets, including Turkey, Brazil, the United States and others.
Sector
Pharmaceuticals
Calendar
28/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
9.22
CNY
Average target price
6.4
CNY
Spread / Average Target
-30.59%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.40% | 1.68B | |
| +19.62% | 43.34B | |
| +20.44% | 21.96B | |
| +10.86% | 14.09B | |
| +13.07% | 13.64B | |
| +37.46% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 002399 Stock
